Jazz Pharmaceuticals (JAZZ) — Fundamentals Overview

By Chris Stiles • Tuesday, October 24 10:04 • Permanent Link

Join us for a quick overview of Jazz Pharmaceuticals, a Pharmaceutical company whose shares moved 0.2% today. Here are some facts about the stock that should help you see the bigger picture:

Jazz Pharmaceuticals has moved -6.0% over the last year, and the S&P 500 logged a change of 11.0%
JAZZ has an average analyst rating of buy and is -35.91% away from its mean target price of $201.06 per share
Its trailing earnings per share (EPS) is $-1.6
Jazz Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -80.5 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $20.29 and its forward P/E ratio is 6.4
The company has a Price to Book (P/B) ratio of 2.32 in contrast to the S&P 500's average ratio of 2.95
Jazz Pharmaceuticals is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
JAZZ has reported YOY quarterly earnings growth of 175.7% and gross profit margins of 0.9%
The company has a free cash flow of $1.29 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.